Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report.
Genomic analysis of circulating tumor DNA (ctDNA) released from cancer cells into the bloodstream has been proposed as a useful method to capture dynamic changes during the course of the disease. In particular, the ability to monitor epidermal growth factor receptor (EGFR) mutation status in cell-free circulating DNA (cfDNA) isolated from advanced non-small cell lung cancer (NSCLC) patientsEGFRcan help to the correct management of the disease and overcome the challenges associated with tumor heterogeneity and insufficient biopsied material to perform key molecular diagnosis. Here, we report a case of long term monitorization ofEGFRmutation status in cfDNA from peripheral blood in an NSCLC patient in, with excellent correlation with clinical evolution.
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Clara Mayo
CM
de Las Casas
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain.
Maria
M
Gonzalez-Cao
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain.
Santiago Viteri
SV
Ramirez
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Nuria Jordana
NJ
Ariza
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Ariadna
A
Balada
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Mónica
M
Garzón
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Cristina
C
Teixidó
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain;; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain;; University Hospital Sagrat Cor, Quirónsalud Group, Barcelona, Spain.
Niki
N
Karachaliou
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain.
Daniela
D
Morales-Espinosa
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain.
Miguel Ángel
MÁ
Molina-Vila
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain;; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain;; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Triasi Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.
Rafael
R
Rosell
circulating free DNA (cfDNA); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC)